Iron Stimulates Urokinase Plasminogen Activator Expression and Activates NF-kappa B in Human Prostate Cancer Cells

References

• Bachman , F . 1987 . “ Fibrinolysis ” . In Thrombosis and Hemostasis , Edited by: Verstraete , M. , Vermylen , J. , Lijnen , R. and Arnout , J. 227 – 266 . Leuven : Belgium University Press .
   Google Scholar
• Achbarou , A , Kaiser , S , Tremblay , G , Ste-Marie , L Brodt , P . 1994 . Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo . Cancer Res , 54 : 2372 – 2377 .
   PubMed Web of Science ®Google Scholar
• Rabbani , S , Harakidas , P , Davidson , D , Henkin , J and Mazar , A . 1995 . Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA) . Int J Cancer , 11 : 840 – 845 .
   Web of Science ®Google Scholar
• Ohta , S , Fuse , H , Fujiuchi , Y , Nagakawa , O and Furuya , Y . 2003 . Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer . Anticancer Res , 23 : 2945 – 2950 .
   PubMed Web of Science ®Google Scholar
• Miyake , H , Hara , I , Yamanaka , K , Gohji , K Arakawa , S . 1999 . Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer . Prostate , 39 : 123 – 129 .
   PubMed Web of Science ®Google Scholar
• Novak , U , Cocks , B and Hamilton , J . 1991 . A labile repressor acts through the NFκB-like binding sites of the human urokinase gene . Nucleic Acids Res , 19 : 3389 – 3393 .
   PubMed Web of Science ®Google Scholar
• Li , H , Ye , X , Mahanivong , C , Bian , D Chun , J . 2005 . Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells . J Biol Chem , 280 : 10564 – 10571 .
   PubMed Web of Science ®Google Scholar
• Sliva , D , English , D , Lyons , D and Lloyd , F Jr. 2002 . Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB . Biochem Biophys Res Commun , 290 : 552 – 557 .
   PubMed Web of Science ®Google Scholar
• Chan , C , Yau , T , Jin , D , Wong , C Fan , S . 2004 . Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma . Clin Cancer Res , 10 : 4140 – 4149 .
   PubMed Web of Science ®Google Scholar
• Lloyd , F Jr. , Slivova , V , Valachovicova , T and Sliva , D . 2003 . Aspirin inhibits highly invasive prostate cancer cells . Int J Oncol , 23 : 1277 – 1283 .
   PubMed Web of Science ®Google Scholar
• Weinberg , E . 1996 . The role of iron in cancer . Eur J Cancer Prev , 5 : 19 – 36 .
   PubMed Web of Science ®Google Scholar
• Huang , X . 2003 . Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal . Mutat Res , 533 : 153 – 171 .
   PubMed Web of Science ®Google Scholar
• Hercberg , S , Estaquio , C , Czernichow , S , Mennen , L Noisette , N . 2005 . Iron status and risk of cancers in the SU.VI.MAX cohort . J Nutr , 135 : 2664 – 2668 .
   PubMed Web of Science ®Google Scholar
• Mainous , A 3rd , Wells , B , Koopman , R , Everett , C and Gill , J . 2005 . Iron, lipids, and risk of cancer in the Framingham offspring cohort . Am J Epidemiol , 161 : 1115 – 1122 .
   PubMed Web of Science ®Google Scholar
• Wells , B , Mainous , A 3rd , Everett , C and Gill , J . 2005 . Iron, cholesterol and the risk of cancer in an 18-year cohort . Asian Pac J Cancer Prev , 6 : 505 – 509 .
   PubMedGoogle Scholar
• Zacharski , L , Chow , B , Howes , P , Lavori , P Shamayeva , G . 2006 . Effect of reduction of iron (Fe) stores on cardiovascular and cancer outcomes in patients with advanced peripheral arterial disease (PAD): VA cooperative study #410, the Iron (Fe) and Atherosclerosis Study (FeAST) . Blood , 108 : 512a – 513a .
   Web of Science ®Google Scholar
• Xiong , S , She , H , Takeuchi , H , Han , B Engelhardt , J . 2003 . Signaling role of intracellular iron in NF-kB activation . J Biol Chem , 278 : 17646 – 17654 .
   PubMed Web of Science ®Google Scholar
• Tsukamoto , H , Lin , M , Ohata , M , Giulivi , C French , S . 1999 . Iron primes hepatic macrophages for NF-κB activation in alcoholic liver injury . Am J Physiol , 277 : G1240 – G1250 .
   PubMed Web of Science ®Google Scholar
• Jimenez , L , Thompson , J , Brown , D , Rahman , I Antonicelli , F . 2000 . Activation of NF-κB by PM10 occurs via an iron-mediated mechanism in the absence of IkB degradation . Toxicol Appl Pharmacol , 166 : 101 – 110 .
   PubMed Web of Science ®Google Scholar
• Reelfs , O , Tyrrell , R and Pourzand , C . 2004 . Ultraviolet A radiation-induced immediate iron release is a key modulator of the activation of NF-kB in human skin fibroblasts . J Invest Dermatol , 122 : 1440 – 1447 .
   PubMed Web of Science ®Google Scholar
• Guillen , C , McInnes , I , Druger , H and Brock , J . 1998 . Iron, lactoferrin and iron reglatory protein activity in the synovium; relative importance of iron loading and the inflammatory response . Ann Rheum Dis , 57 : 309 – 314 .
   PubMed Web of Science ®Google Scholar
• van Asbeck , B , Georgiou , N , van der Bruggen , T , Oudshoorn , M Nottet , H . 2001 . Anti-HIV effect of iron chelators: different mechanisms involved . J Clin Virol , 20 : 141 – 147 .
   PubMed Web of Science ®Google Scholar
• Shedlofsky , S , Bonkowsky , H , Sinclair , P , Sinclair , J Bement , W . 1983 . Iron loading of cultured hepatocytes. Effect of iron on 5-aminolaevulinate synthase is independent of lipid peroxidation . Biochem J , 212 : 321 – 330 .
   PubMed Web of Science ®Google Scholar
• Berse , B , Hunt , J , Diegel , R , Morganelli , P Yeo , K-T . 1999 . Hypoxia augments cytokine (transforming growth factor-beta (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts . Clin Exp Immunol , 115 : 176 – 182 .
   PubMed Web of Science ®Google Scholar
• Scott , J , Homcy , C , Khaw , B and Rabito , C . 1988 . Quantitation of oxidation in a renal epithelial cell line . Free Radic Biol Med , 4 : 79 – 83 .
   PubMed Web of Science ®Google Scholar
• Barchowsky , A , Dudek , E , Treadwell , M and Wetterhahn , K . 1996 . Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells . Free Radic Biol Med , 21 : 783 – 790 .
   PubMed Web of Science ®Google Scholar
• Barchowsky , A , Munro , S , Morana , S , Vincenti , M and Treadwell , M . 1995 . Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa BAP-1 in endothelial cells . Am J Physiol , 269 : L82 – L836 .
   Google Scholar
• Barchowsky , A , Roussel , R , Krieser , R , Mossman , B and Treadwell , M . 1998 . Expression and activity of urokinase and its receptor in endothelial and pulmonary epithelial cells exposed to asbestos . Toxicol Appl Pharmacol , 152 : 38 – 396 .
   Web of Science ®Google Scholar
• Halliwell , N and Gutteridge , J . 1984 . Oxygen toxicity, oxygen radicals, transition metals and disease . Biochem J , 219 : 1 – 14 .
   PubMed Web of Science ®Google Scholar
• Sheng , S . 2001 . The urokinase-type plasminogen activator system in prostate cancer metastasis . Cancer Metastasis Rev , 20 : 287 – 296 .
   PubMed Web of Science ®Google Scholar
• Dunbar , S , Ornstein , D and Zacharski , L . 2000 . Treatment of cancer with inhibitors of the plasminogen activator-plasmin system . Exp Opin Invest Drugs , 9 : 2085 – 2092 .
   PubMed Web of Science ®Google Scholar
• Pulukuri , S , Gondi , C , Lakka , S , Jutla , A Estes , N . 2005 . RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival and tumorigenicity in vivo . J Biol Chem , 280 : 36529 – 36540 .
   PubMed Web of Science ®Google Scholar
• Wesley , U , McGroarty , M and Homoyouni , A . 2005 . Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway . Cancer Res , 65 : 1325 – 1334 .
   PubMed Web of Science ®Google Scholar
• Sabbisetti , V , Chigurupati , S , Thomas , S and Shah , G . 2006 . Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion . Int J Cancer , 118 : 2694 – 2702 .
   PubMed Web of Science ®Google Scholar
• Ohta , S , Niiya , K , Sakuragawa , N and Fuse , H . 2000 . Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells . Thromb Res , 97 : 343 – 347 .
   PubMed Web of Science ®Google Scholar
• Hall , C , Tsan , R , Mugnai , G , Mazar , A Radinsky , R . 2004 . Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA) . Prostate , 59 : 16 – 176 .
   Web of Science ®Google Scholar
• Lui , D and Rabbani , S . 1995 . Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3 . Prostate , 27 : 269 – 276 .
   PubMed Web of Science ®Google Scholar
• Bindukumar , B , Schwartz , S , Nair , M , Aalinkeel , R Kawinski , E . 2005 . Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth . Neoplasia , 7 : 241 – 252 .
   PubMed Web of Science ®Google Scholar
• Evans , C , Stapp , E , Dall'Era , M , Juarez , J and Yang , J . 2001 . Regulation of u-PA gene expression in human prostate cancer . Int J Cancer , 94 : 390 – 395 .
   PubMed Web of Science ®Google Scholar
• Torti , F and Torti , S . 2002 . Regulation of ferritin genes and protein . Blood , 99 : 3505 – 3516 .
   PubMed Web of Science ®Google Scholar
• Sturrock , A , Alexander , J , Lamb , J , Craven , C and Kaplan , J . 1990 . Characterization of a transferrin-independent uptake system for iron in HeLa cells . J Biol Chem, , 265 : 3139 – 3145 .
   PubMed Web of Science ®Google Scholar
• Inman , R and Wessling-Resnick , M . 1993 . Characterization of transferrin-independent iron transport in K562 cells . J Biol Chem , 268 : 8521 – 8528 .
   PubMed Web of Science ®Google Scholar
• Richardson , D . 2000 . The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell . Eur J Biochem , 267 : 1290 – 1298 .
   PubMedGoogle Scholar
• Richardson , D and Baker , E . 1991 . The uptake of inorganic iron complexes by human melanoma cells . Biochim Biophys Acta , 1093 : 20 – 28 .
   PubMed Web of Science ®Google Scholar
• Parkes , J , Randell , E , Olivieri , N and Templeton , D . 1995 . Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells . Biochim Biophys Acta , 1243 : 373 – 380 .
   PubMed Web of Science ®Google Scholar
• Radha , K , Sugiki , M , Harish Kumar , M , Omura , S and Maruyama , M . 2005 . Post-transcriptional regulation of plasminogen activator inhibitor-1 by intracellular iron in cultured human lung fibroblasts—interaction of an 81-kDa nuclear protein with the 3′-UTR . J Thromb Haemost , 3 : 1001 – 1008 .
   PubMed Web of Science ®Google Scholar
• Radha , K , Sugiki , M , Yoshida , E , Harish Kumar , M Omura , S . 2005 . Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells—involvement of a mRNA-binding nuclear protein . Thromb Res , 116 : 255 – 263 .
   PubMed Web of Science ®Google Scholar
• Hasegawa , T , Sorensen , L , Ooi , H and Marshall , B . 1999 . Decreased intracellular iron availability suppresses epithelial cell surface plasmin generation . Am J Respir Cell Mol Biol , 21 : 275 – 282 .
   PubMed Web of Science ®Google Scholar
• Luo , J-L , Kamata , H and Karin , M . 2005 . IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy . J Clin Invest , 115 : 2625 – 2632 .
   PubMed Web of Science ®Google Scholar
• Tantivejkul , K , Loberg , R , Mawocha , S , Day , L John , L . 2005 . PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism . J Cell Biochem , 96 : 641 – 652 .
   PubMed Web of Science ®Google Scholar
• Sweeney , C , Li , L , Shanmugam , R , Bhat-Natshatri , P Jayaprakasan , V . 2004 . Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate . Clin Cancer Res , 10 : 5501 – 5507 .
   PubMed Web of Science ®Google Scholar
• Lindholm , P , Bub , J , Kaul , S , Shidham , V and Kajdacy-Balla , B . 2000 . The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior . Clin Exp Metastasis , 18 : 471 – 479 .
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech , J , Mellado , B , Ferrer , B , Truan , D Codony-Servat , J . 2005 . Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse . Br J Cancer , 93 : 1285 – 1294 .
   PubMed Web of Science ®Google Scholar
• Lessard , L , Begin , L , Gleave , M , Mes-Masson , A and Saad , F . 2005 . Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study . Br J Cancer , 93 : 1019 – 1023 .
   PubMed Web of Science ®Google Scholar
• Fradat , V , Lessard , L , Begin , L , Karakiewicz , P Masson , A . 2004 . Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer . Clin Cancer Res , 10 : 8460 – 8464 .
   PubMed Web of Science ®Google Scholar
• Ross , J , Kallakury , B , Sheehan , C , Fisher , H Kaurman , R Jr. 2004 . Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence . Clin Cancer Res , 10 : 2466 – 2472 .
   PubMed Web of Science ®Google Scholar
• Ismail , H , Lessard , L , Mes-Masson , A and Saad , F . 2004 . Expression of NF-kappaB in prostate cancer lymph node metastases . Prostate , 58 : 308 – 313 .
   PubMed Web of Science ®Google Scholar
• Dhanalakshmi , S , Agarwal , R and Agarwal , C . 2003 . Inhibition of NF-kappaB pathway in grape seed extract-induced apoptotic death of human prostate carcinoma DU145 cells . Int J Oncol , 2003 : 721 – 727 .
   Google Scholar
• Kikuchi , E , Horiguchi , Y , Nakashima , J , Kuroda , K Oya , M . 2003 . Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice . Cancer Res , 63 : 107 – 110 .
   PubMed Web of Science ®Google Scholar
• Papandreou , C , Daliani , D , Nix , D , Yang , H Madden , T . 2004 . Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer . J Clin Oncol , 22 : 2108 – 2121 .
   PubMed Web of Science ®Google Scholar
• Liu , Y , Shimizu , I , Omoya , T , Ito , S Gu , X-S . 2002 . Protective effect of estradiol on hepatocytic oxidative damage . World J Gastroenterology , 8 : 363 – 366 .
   PubMed Web of Science ®Google Scholar
• Inoue , H , Shimizu , I , Lu , G , Itonaga , M Cui , X . 2003 . Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-β in cultured rat hepatocytes . Dig Dis Sci , 48 : 570 – 580 .
   PubMed Web of Science ®Google Scholar
• Yajun , Z , Hongshan , C , Baoxi , S , Dengbing , Y Jianhua , S . 2005 . Translocation of bax in rat hepatocytes cultured with ferric nitrilotriacetate . Life Sciences , 76 : 2763 – 2772 .
   PubMed Web of Science ®Google Scholar
• Bradley , S , Gosriwatana , I , Srichairatanakool , S , Hider , R and Porter , J . 1997 . Non-transferrin-bound iron induced by myeloablative chemotherapy . Br J Haematol , 99 : 337 – 343 .
   PubMed Web of Science ®Google Scholar
• Harrison , P , Marwah , S , Hughes , R and Bareford , D . 1994 . Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy . J Clin Pathol , 47 : 350 – 352 .
   PubMed Web of Science ®Google Scholar
• Harrison , P , Neilson , J , Marwah , S , Madden , L Bareford , D . 1996 . Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation . J Clin Pathol , 49 : 853 – 856 .
   PubMed Web of Science ®Google Scholar
• Grosse , R , Lund , U , Caruso , V , Fischer , R Janka , G . 2005 . Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major . Ann NY Acad Sci , 1054 : 429 – 432 .
   PubMed Web of Science ®Google Scholar
• Scheiber-Mojdehkar , B , Lutzky , B , Schaufler , R , Sturm , B and Goldenberg , H . 2004 . Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation . J Am Soc Nephrol , 15 : 1648 – 1655 .
   PubMed Web of Science ®Google Scholar
• Breuer , W , Ronson , A , Slotki , I , Abramov , A Hershko , C . 2000 . The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation . Blood , 95 : 2975 – 2982 .
   PubMed Web of Science ®Google Scholar
• Auerbach , M , Ballard , H , Trout , J , McIlwain , M Ackerman , A . 2004 . Intravenous iron optimizes the response to recombinant human erythropoitein in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial . J Clin Oncol , 22 : 1301 – 1307 .
   PubMed Web of Science ®Google Scholar
• de Valk , B , Addicks , M , Gosriwatana , I , Lu , S Hider , R . 2000 . Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes . Eur J Clin Invest , 30 : 248 – 251 .
   PubMed Web of Science ®Google Scholar
• Grootveld , M , Bell , J , Halliwell , B , Aruoma , O Bomford , A . 1989 . Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis . J Biol Chem , 262 : 4417 – 4422 .
   Google Scholar
• Pahl , P and Horwitz , L . 2005 . Cell permeable iron chelators as potential cancer chemotherapeutic agents . Cancer Invest , 23 : 683 – 691 .
   PubMed Web of Science ®Google Scholar
• Richardson , D . 2005 . Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer . Curr Med Chem , 12 : 2711 – 2729 .
   PubMed Web of Science ®Google Scholar
• Kovacevik , Z and Richardson , D . 2006 . The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer . Carcinogenesis , 27 : 2355 – 2366 .
   PubMed Web of Science ®Google Scholar
• Dreicer , R , Kemp , J , Stegink , L , Cardillo , T Davis , C . 1997 . A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer . Cancer Invest , 15 : 311 – 317 .
   PubMed Web of Science ®Google Scholar
• Porter , J , Rafique , R , Srichairatanakool , S , Davis , B Shah , F . 2005 . Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use . Ann NY Acad Sci , 1054 : 155 – 168 .
   PubMed Web of Science ®Google Scholar